Brief: Neovacs Announces Clinical Advisory Board Meeting To Design Phase III Study For IFNalpha Kinoide In Lupus
31/01/2019 16:57
Jan 31 (Reuters) - NEOVACS SA ALNEV.PA :
* REG-NEOVACS ANNOUNCES ITS CLINICAL ADVISORY BOARD MEETING
TO
DESIGN THE PHASE III STUDY FOR IFNALPHA KINOIDE IN LUPUS - PARIS
FEBRUARY 11TH
Source text for Eikon: ID:nGNE736pS7
Further company coverage: ALNEV.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com;))
Recent news on Neovacs SA
See all newsBrief: Neovacs And FOCH Hospital Commit To Partnership On Research In Pneumology And Allergology
Brief: Neovacs Presented Latest Results On Its Vaccine Candidates Targeting Allergies
Brief: Neovacs H1 Gross Cash Position Down At EUR 6.2 Mln
Brief: Neovacs: Signature Of Trust Agreement For Equitization Of Bonds Redeemable In Shares With Share Warrants
Brief: Neovacs Launches A Public Offering Of Bonds Redeemable In Shares With Stock Warrants